These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

134 related articles for article (PubMed ID: 12711184)

  • 1. Pharmacokinetics and delivery of the anti-influenza prodrug oseltamivir to the small intestine and colon using site-specific delivery capsules.
    Oo C; Snell P; Barrett J; Dorr A; Liu B; Wilding I
    Int J Pharm; 2003 May; 257(1-2):297-9. PubMed ID: 12711184
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Assessment of levetiracetam bioavailability from targeted sites in the human intestine using remotely activated capsules and gamma scintigraphy: Open-label, single-dose, randomized, four-way crossover study in healthy male volunteers.
    Stockis A; Sargentini-Maier ML; Otoul C; Connor A; Wilding I; Wray H
    Clin Ther; 2010 Sep; 32(10):1813-21. PubMed ID: 21194605
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Lack of pharmacokinetic interaction between the oral anti-influenza neuraminidase inhibitor prodrug oseltamivir and antacids.
    Snell P; Oo C; Dorr A; Barrett J
    Br J Clin Pharmacol; 2002 Oct; 54(4):372-7. PubMed ID: 12392584
    [TBL] [Abstract][Full Text] [Related]  

  • 4. The anti-influenza drug oseltamivir exhibits low potential to induce pharmacokinetic drug interactions via renal secretion-correlation of in vivo and in vitro studies.
    Hill G; Cihlar T; Oo C; Ho ES; Prior K; Wiltshire H; Barrett J; Liu B; Ward P
    Drug Metab Dispos; 2002 Jan; 30(1):13-9. PubMed ID: 11744606
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Pharmacokinetics of anti-influenza prodrug oseltamivir in children aged 1-5 years.
    Oo C; Hill G; Dorr A; Liu B; Boellner S; Ward P
    Eur J Clin Pharmacol; 2003 Sep; 59(5-6):411-5. PubMed ID: 12910331
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Pharmacokinetics and dosage recommendations for an oseltamivir oral suspension for the treatment of influenza in children.
    Oo C; Barrett J; Hill G; Mann J; Dorr A; Dutkowski R; Ward P
    Paediatr Drugs; 2001; 3(3):229-36. PubMed ID: 11310719
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Clinical pharmacokinetics of the prodrug oseltamivir and its active metabolite Ro 64-0802.
    He G; Massarella J; Ward P
    Clin Pharmacokinet; 1999 Dec; 37(6):471-84. PubMed ID: 10628898
    [TBL] [Abstract][Full Text] [Related]  

  • 8. A randomized, open-label, 2-period, crossover bioequivalence study of two oral formulations of 75 mg oseltamivir in healthy Thai volunteers.
    Kongpatanakul S; Chatsiricharoenkul S; Panich U; Sathirakul K; Pongnarin P; Sangvanich P
    Int J Clin Pharmacol Ther; 2008 Dec; 46(12):654-62. PubMed ID: 19049700
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Lack of pharmacokinetic interaction between the oral anti-influenza prodrug oseltamivir and aspirin.
    Oo C; Barrett J; Dorr A; Liu B; Ward P
    Antimicrob Agents Chemother; 2002 Jun; 46(6):1993-5. PubMed ID: 12019123
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Assessment of lumiracoxib bioavailability from targeted sites in the human intestine using remotely activated capsules and gamma scintigraphy.
    Wilding IR; Connor AL; Carpenter P; Rordorf C; Branson J; Milosavljev S; Scott G
    Pharm Res; 2004 Mar; 21(3):443-6. PubMed ID: 15070094
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Assessment of tacrolimus absorption from the human intestinal tract: open-label, randomized, 4-way crossover study.
    Tsunashima D; Kawamura A; Murakami M; Sawamoto T; Undre N; Brown M; Groenewoud A; Keirns JJ; Holman J; Connor A; Wylde H; Wilding I; Ogawara K; Sako K; Higaki K; First R
    Clin Ther; 2014 May; 36(5):748-59. PubMed ID: 24680768
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Pharmacokinetics of aminophylline delivered to the small intestine and colon using remote controlled capsules.
    Liu HY; Pi XT; Zheng XL; Hou WS; Cui JG
    Chin Med J (Engl); 2010 Feb; 123(3):320-5. PubMed ID: 20193253
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Pharmacokinetics of oseltamivir: an oral antiviral for the treatment and prophylaxis of influenza in diverse populations.
    Davies BE
    J Antimicrob Chemother; 2010 Apr; 65 Suppl 2(Suppl 2):ii5-ii10. PubMed ID: 20215135
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Evaluation of regional gastrointestinal absorption of edoxaban using the enterion capsule.
    Parasrampuria DA; Kanamaru T; Connor A; Wilding I; Ogata K; Shimoto Y; Kunitada S
    J Clin Pharmacol; 2015 Nov; 55(11):1286-92. PubMed ID: 25969414
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Oseltamivir.
    Bardsley-Elliot A; Noble S
    Drugs; 1999 Nov; 58(5):851-60; discussion 861-2. PubMed ID: 10595865
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Oseltamivir oral suspension and capsules are bioequivalent for the active metabolite in healthy adult volunteers.
    Lennon S; Barrett J; Kirkpatrick C; Rayner C
    Int J Clin Pharmacol Ther; 2009 Aug; 47(8):539-48. PubMed ID: 19640363
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Active metabolite from Tamiflu solution is bioequivalent to that from capsule delivery in healthy volunteers: a cross-over, randomised, open-label study.
    Brewster M; Smith JR; Dutkowski R; Robson R
    Vaccine; 2006 Nov; 24(44-46):6660-3. PubMed ID: 16797800
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Pharmacokinetic Modeling and Monte Carlo Simulation to Predict Interindividual Variability in Human Exposure to Oseltamivir and Its Active Metabolite, Ro 64-0802.
    Ito M; Kusuhara H; Ose A; Kondo T; Tanabe K; Nakayama H; Horita S; Fujita T; Sugiyama Y
    AAPS J; 2017 Jan; 19(1):286-297. PubMed ID: 27800573
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Pharmacoscintigraphic assessment of the regional drug absorption of the dual angiotensin-converting enzyme/neutral endopeptidase inhibitor, M100240, in healthy volunteers.
    Martin NE; Collison KR; Martin LL; Tardif S; Wilding I; Wray H; Barrett JS
    J Clin Pharmacol; 2003 May; 43(5):529-38. PubMed ID: 12751274
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Regional Gastrointestinal Absorption of Apixaban in Healthy Subjects.
    Byon W; Nepal S; Schuster AE; Shenker A; Frost CE
    J Clin Pharmacol; 2018 Jul; 58(7):965-971. PubMed ID: 29578609
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.